ArticleJournal of thoracic disease2025
Integrative analysis of fatty acid metabolism and identification of
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dysregulation of fatty acid (FA) metabolism represents a critical contribution to the tumorigenesis and progression of lung adenocarcinoma (LUAD). This study aimed to identify the roles of FA metabolism and search for potential therapeutic targets. Methods: The genomic and clinical data from The Cancer Genome Atlas (TCGA)-LUAD cohort underwent univariate and least absolute shrinkage and selection operator (LASSO) Cox regression analyses to establish a FA metabolism-related gene (FAMG) signature. Immunotherapy efficacy was evaluated via the Tumor Immune Dysfunction and Exclusion (TIDE) algorithm. Pharmacological sensitivity to conventional chemotherapeutic agents and molecular targeted therapies was evaluated using the "pRRophetic" R package. Through integrative multi-omics analysis, Results: The FAMG prognostic signature indicated clinical utility in predicting patient outcomes and stratifying survival probabilities. The signature showed predictive capacity for therapeutic responses across immunotherapy, chemotherapy, and targeted drugs, supporting precision oncology applications. Experimental validation confirmed that Conclusions: This work delineates FA metabolic heterogeneity and its predictive function of personalized treatment in LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.